National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Tivozanib (Fotivda®) is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.

NCPE Assessment Process Complete
Rapid review commissioned 09/01/2019
Rapid review completed 24/01/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tivozanib compared with the current standard of care.

The HSE has approved reimbursement following confidential price negotiations August 2019.